Tumor-Targeted Bacterial Vaccine Induces In Situ Immunogenic Cell Death for Cancer Immunotherapy
Nano Letters · 2025
DOI: 10.1021/acs.nanolett.5c03938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, 2025. Verfasst von Yi Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230601, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Immunogenic Cell Death, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Anhui Provincial Natural Science Foundation.
Abstract (Originalsprache)
The immunosuppressive nature and low antigenicity of solid tumors present major obstacles for effective cancer vaccination. Here, we report a live bacteria-based vaccine platform engineered by coating attenuated Salmonella (SAL) with a cancer cell membrane (CCM), integrating pathogenic adjuvants and autologous tumor antigens into a single entity. This CCM@SAL system leverages bacterial immunogenicity to induce immunogenic cell death (ICD) within the tumor microenvironment, promoting in situ release of endogenous antigens and damage-associated molecular patterns. These events synergize to prime antigen-presenting cells and activate tumor-specific T cells. Notably, CCM coating reduces bacterial clearance by phagocytes and enhances tumor accumulation. The combination of ICD induction and tumor-targeted antigen delivery enables a self-amplifying vaccination cycle within the tumor. This in situ vaccination induces durable systemic immunity and suppresses tumor progression in multiple murine models. By integrating tumor targeting, ICD induction, and antigen presentation, CCM@SAL offers a broadly applicable strategy to improve cancer vaccine efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230601, China.
- State Key Laboratory of Immune Response and Immunotherapy, Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230…
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
- Wuxi Institute for Drug Control, Wu Xi 214000, China.
- School of Chemistry and Chemical Engineering, Anhui University, Hefei 230601, China.
ORCID-Profile: Min Li
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- Anhui Provincial Natural Science Foundation
- USTC Research Funds of the Double First-Class Initiative
- China Postdoctoral Science Foundation
- University of Science and Technology of China
- National Key Research and Development Program of China
- Anhui Provincial Department of Science and Technology
Zitieren
APA
Wu, Y., Wu, N., Xu, Y., Yang, C., Zhou, H., Jiang, W., Shen, J., Liu, H., & Li, M. (2025). Tumor-Targeted Bacterial Vaccine Induces In Situ Immunogenic Cell Death for Cancer Immunotherapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.5c03938
Vancouver
Wu Y, Wu N, Xu Y, Yang C, Zhou H, Jiang W, et al. Tumor-Targeted Bacterial Vaccine Induces In Situ Immunogenic Cell Death for Cancer Immunotherapy. Nano Letters. 2025. doi:10.1021/acs.nanolett.5c03938
BibTeX
@article{Wu2025,
author = {Wu, Yi and Wu, Namei and Xu, Youcui and Yang, Chen and Zhou, Han and Jiang, Wei and Shen, Jizhou and Liu, Hang and Li, Min},
title = {Tumor-Targeted Bacterial Vaccine Induces In Situ Immunogenic Cell Death for Cancer Immunotherapy},
journal = {Nano Letters},
year = {2025},
doi = {10.1021/acs.nanolett.5c03938}
}
EUVIMED